PRDM16 Antibody - #DF13303

Fig. 7: Clinical outcomes associated with the expression of the IGSF9, PRDM16, and ALDH2 proteins in 86 patients with IMPC. a–f Images of immunohistochemical staining for IGSF9, PRDM16, and ALDH2 in patients with IMPC (n = 86). The upper panel shows low expression of IGSF9, PRDM16, and ALDH2 in patients with IMPC; the lower panel shows high expression of the IGSF9, PRDM16, and ALDH2 proteins in patients with IMPC, ×400 magnification. g The association of IGSF9, PRDM16, and ALDH2 protein expression with OS and DFS. The upper panel shows OS, and the lower panel shows DFS, with patients with IMPC stratified by high and low protein expression. Log-rank test, two-sided. The P values for OS of IGSF9, PRDM16, and ALDH2 were 0.000, 0.004, and 0.004, respectively; the P values for DFS of IGSF9, PRDM16, and ALDH2 were 0.010, 0.003, and 0.001, respectively. P 

Figure 4. |Protein expression of genes related to antioxidant, adipogenic differentiation and beiging of the WAT in the retroperitoneal depot was detected by western-blot.(b) effect of CHP on lipid metabolism and adipocyte differentiation-related protein expression in obese mice induced by HFD

Figure 4. |Protein expression of genes related to antioxidant, adipogenic differentiation and beiging of the WAT in the retroperitoneal depot was detected by western-blot.(b) effect of CHP on lipid metabolism and adipocyte differentiation-related protein expression in obese mice induced by HFD; (c) CHP upregulation protein expression of white adipose browning gene in obese mice induced by HFD. Control group (CON): normal feed; high-fat diet group (HFD): highfat diet; high-fat diet feed supplemented orlistat (HFD + OST): HFD was fed for 12 weeks, orlistat was gavaged at 15.6 mg/kg bw/day, as a positive control group; CHP group supplemented with high-fat feed (HFD + CHP): HFD was fed for 12 weeks, CHP was gavaged 250 mg/kg bw/ day. Values are expressed as the mean ± standard deviation, n = 3. **p < 0.01, *p < 0.05.

Figure 5 Prdm16 and Ucp-1 expression in subcutaneous WAT and comparison of serum leptin levels in each group. (A and B) H&E staining in the inguinal subcutaneous WAT of mice induced by DIO and MSG (scale bar = 110 μm). (C and D) Prdm16 expression in the adipose tissue of mice induced by DIO and MSG according to Western blot. (E and F) Ucp-1 expression in the adipose tissue of mice induced by DIO and MSG according to Western blot. (G) Immunoreactivity of Prdm16 in the adipose tissue of mice induced by a high-fat diet and presented as the mean ± SD (n = 3). #P < 0.05 vs the DIO group. (H) Immunoreactivity of Prdm16 in the adipose tissue of mice induced by MSG and presented as the mean ± SD (n = 3). #P < 0.05 vs the MSG group. (I) Immunoreactivity of Ucp-1 in the adipose tissue of mice induced by a high-fat diet and presented as the mean ± SD (n = 3). **P < 0.01 vs the NC group. ##P < 0.01 vs the DIO group. (J) Immunoreactivity of Ucp-1 in the adipose tissue of mice induced by MSG and presented as the mean ± SD (n = 3). **P < 0.01 vs the NC group. ###P < 0.001 vs the MSG group. Abbreviations: DIO, diet-induced obesity; MSG, mice with MSG-induced obesity; NC, normal control; Prdm16, PR domain containing 16; Ucp-1, uncoupling protein-1.